Next Article in Journal
Prognostic Significance of Lactate Dehydrogenase-to-Albumin Ratio and Neutrophil Percentage-to-Albumin Ratio in IgA Nephropathy
Previous Article in Journal
Antipsychotic Drug Cariprazine Induces Distinct Cell Death Mechanisms in HeLa and HCT116 Cells as a Potential Inhibitor of Qi-Site of Cytochrome bc1 Reductase
Previous Article in Special Issue
Atezolizumab Plus Bevacizumab Combination Therapy in Unresectable Hepatocellular Carcinoma: An Institutional Experience
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Biomedicines
Volume 14
Issue 2
10.3390/biomedicines14020319
biomedicines-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Adverse Histopathological Features in Colorectal Cancer Associated with KRAS rs61764370 SNP: A Preliminary Study

by
Tradian Ciprian Berisha
1,2,†,
Mihai Gabriel Cucu
3,4,†,
Alexandru Calotă-Dobrescu
4,
Simona Serban Sosoi
3,
Ana-Maria Ciurea
2,5,
Alina Maria Mehedințeanu
2,
Puiu Olivian Stovicek
2,6,
Ramona Adriana Schenker
2,
Cecil Sorin Mirea
7,
Monica-Laura Cara
2,8,*,
Florin Burada
3,4,*,‡ and
Michael Schenker
2,5,‡
1
Doctoral School, University of Medicine and Pharmacy Craiova, 200349 Craiova, Romania
2
Sf. Nectarie Oncology Center, 200347 Craiova, Romania
3
Human Genomics Laboratory, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania
4
Regional Centre of Medical Genetics Dolj, Emergency Clinical County Hospital Craiova, 200642 Craiova, Romania
5
Department of Oncology, Faculty of Medicine, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania
6
Department of Pharmacology, Faculty of Nursing, Târgu Jiu Subsidiary, “Titu Maiorescu” University, 040441 Bucharest, Romania
7
Department of Surgical Semiology, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania
8
Department of Public Health, Faculty of Medicine, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania
*
Authors to whom correspondence should be addressed.
†
These authors contributed equally to this work.
‡
These authors also contributed equally to this work.
Biomedicines 2026, 14(2), 319; https://doi.org/10.3390/biomedicines14020319
Submission received: 30 December 2025 / Revised: 28 January 2026 / Accepted: 28 January 2026 / Published: 30 January 2026
(This article belongs to the Special Issue Recent Advances in Gastrointestinal Cancers: From Microbiota Modulation to New Therapeutic Approaches—2nd Edition)
Browse Figures
Versions Notes

Abstract

Background/Objectives: The KRAS rs61764370 T>G single-nucleotide polymorphism (SNP), located in a let-7 microRNA binding site within the 3′ untranslated region (3′UTR) of the KRAS gene, may modulate tumor aggressiveness by altering post-transcriptional gene regulation. This study evaluated its association with adverse histopathological features in colorectal cancer (CRC). Methods: A preliminary study on 83 CRC patients carrying either the TT (wild-type, n = 64) or TG (heterozygous, n = 19) genotype was analyzed. Clinicopathological variables included patient sex, tumor location, American Joint Committee on Cancer (AJCC) staging system, histological grade, perineural invasion (PNI), and lymphovascular invasion (LVI). A composite “tumor aggressiveness” score was defined based on the presence of Grade 3 differentiation, LVI, and/or PNI. Group comparisons were performed using the Chi-square test or Fisher’s exact test, as appropriate. Results: No statistically significant differences were observed in sex (p = 0.689), tumor location (p = 0.781), or stage at diagnosis (p = 0.812). Poorly differentiated tumors (Grade 3) were present in 20.3% of TT patients and absent in TG carriers (p = 0.06), while low-grade tumors (Grade 1) were more prevalent among TG patients (47.4%) compared to TT (29.7%). The composite high-aggressiveness score was lower in TG (36.8%) than in TT (48.4%), while co-occurrence of PNI and LVI was similar in both groups (~26%). Conclusions: Although no significant associations were identified, TG carriers showed a tendency toward lower-grade, less aggressive tumors. Given the limited sample size, these findings should be interpreted with caution, necessitating larger cohorts in order to validate results.

1. Introduction

Colorectal cancer (CRC) is one of the most frequently diagnosed malignancies worldwide, representing a significant global health burden [1,2]. According to GLOBOCAN 2022 data, CRC ranks third in incidence and second in cancer-related mortality globally, with over 1.9 million new cases and approximately 935,000 deaths estimated in 2020 alone [3,4]. The epidemiological burden remains substantial in Eastern Europe, where Romania reports one of the highest mortality rates among EU countries [4].
Although the TNM staging system remains the cornerstone of prognostication in CRC, numerous histopathological features provide valuable additional prognostic information. These include tumor grade, mucinous or signet-ring cell histology, lymphovascular invasion (LVI), perineural invasion (PNI), tumor budding, and the presence of tumor deposits [5,6,7,8,9,10,11]. Poorly differentiated tumors, classified by low glandular formation (<50%), have been consistently associated with unfavorable outcomes and higher metastatic potential [5]. Mucinous adenocarcinomas and signet-ring cell carcinomas, considered high-grade subtypes, are known for their aggressive behavior and chemoresistance [6].
Lymphovascular invasion, the presence of tumor cells in endothelial-lined lymphatic or blood vessels, represents a key step in metastatic dissemination and correlates with poor prognosis, particularly in stage II disease [7,9,11]. Perineural invasion, characterized by cancer cell infiltration around or through nerves, is also recognized as an independent predictor of local recurrence, distant metastases, and decreased survival [8,9,10]. Additionally, tumor budding—defined as the presence of isolated single cells or small clusters (<5 cells) at the invasive front—has emerged as an important marker of aggressive biological behavior and adverse outcomes [12].
In recent years, efforts have been made to identify molecular markers that could refine prognostic stratification beyond classical histopathology. Among them, the germline single-nucleotide polymorphism rs61764370, located in the 3′ untranslated region (3′UTR) of the KRAS oncogene at the let-7 microRNA binding site (LCS6), has attracted attention [13,14,15,16,17]. The presence of the G allele disrupts binding of the tumor-suppressive let-7 family of microRNAs, potentially leading to increased KRAS expression and downstream activation of RAS-MAPK signaling [18].
The let-7 family of microRNAs was originally identified in Caenorhabditis elegans as a key regulator of developmental timing and represents one of the first microRNA families shown to be evolutionarily conserved across species [19,20]. In humans, let-7 microRNAs (hsa-let-7a–h) act predominantly as tumor suppressors by regulating the expression of genes involved in cell cycle progression, cellular differentiation, and apoptosis. Dysregulation and reduced expression of let-7 family members have been reported in multiple malignancies, including colorectal cancer, and have been associated with aggressive tumor behavior and unfavorable clinical outcomes [21,22].
Let-7 microRNAs exert their post-transcriptional regulatory function by binding to complementary sequences within the 3′ untranslated regions (3′UTRs) of target messenger RNAs, leading to translational repression or mRNA destabilization. The KRAS oncogene contains a conserved let-7 complementary site (LCS6) within its 3′UTR [23,24]. A single-nucleotide polymorphism, rs61764370 (T>G), located within this region, has been shown to disrupt let-7 binding, resulting in altered KRAS regulation and increased oncogenic signaling. In addition to let-7, other microRNAs, including miR-98, have also been reported to target the LCS6 sequence, underscoring the functional relevance of this regulatory region in KRAS-mediated tumorigenesis [25,26].
Initial studies linked this polymorphism with poor prognosis in several cancers, including ovarian and lung cancer [18,27], and raised interest in its possible predictive role in colorectal cancer. However, the results have been contradictory. Some studies suggested that the variant G allele may be associated with improved response to anti-EGFR therapy in metastatic CRC [27], while others found no significant correlation with treatment response or overall prognosis [28,29]. Meta-analyses have also failed to confirm a consistent association between rs61764370 and survival outcomes in CRC, highlighting the need for further exploration [30,31].
Given the biological plausibility and its potential regulatory effect on KRAS expression, this study aims to explore possible correlations between the rs61764370 SNP and adverse histopathological features in a cohort of colorectal cancer patients. Specifically, the study investigates whether the presence of the G allele correlates with poor differentiation, LVI, PNI, and tumor budding, with the goal of assessing its potential prognostic relevance in clinical practice.

2. Materials and Methods

This preliminary analysis includes 83 patients referred for rs61764370 genotyping at the Human Genomics Laboratory of the University of Medicine and Pharmacy in Craiova, Romania, all with histologically confirmed colorectal adenocarcinoma.
The clinical and histopathological variables collected were patient sex, tumor location (colon or rectum), stage at diagnosis (I–IV), histological grade (1–3), presence of perineural invasion (PNI), and lymphovascular invasion (LVI) (Table 1).
To capture the biological complexity of tumor behavior, we introduced a composite aggressiveness score, defined as the presence of at least one of the following adverse histopathological features: poor differentiation (Grade 3), lymphovascular invasion (LVI), or perineural invasion (PNI), and dichotomized tumors as low-grade (Grade 1) versus high-grade (Grades 2 or 3).

2.1. SNP Genotyping Analysis

Genomic DNA was extracted from peripheral blood samples using the Wizard® Genomic DNA Purification Kit (Promega, Madison, WI, USA) following the manufacturer’s protocol. DNA concentration and purity were assessed spectrophotometrically; all samples were diluted to a working concentration of 10–20 ng/μL and the target for purity was at least a 1.7 absorption rate at 260 and 320 nm. The single-nucleotide polymorphism rs61764370 in the 3′ untranslated region (3′UTR) of the KRAS gene was genotyped using the TaqMan® SNP Genotyping Assay (Applied Biosystems, Waltham, MA, USA), Assay ID: C_89129087_10), which discriminates between the wild-type T allele and the variant G allele. Each reaction was performed in a final volume of 5 μL, containing the following: 2.5 μL of TaqMan® Genotyping Master Mix (Applied Biosystems), 0.25 μL of 20× SNP Genotyping Assay Mix (primers and VIC/FAM-labeled probes), 1.25 μL of genomic DNA (10–20 ng), 1 μL of nuclease-free water.
Reactions were carried out in 384-well optical plates using a ViiA7™ Real-Time PCR System (Thermo Fisher Scientific, Waltham, MA, USA). Thermal cycling conditions consisted of an initial denaturation at 95 °C for 10 min, followed by 40 cycles at 95 °C for 15 s and 60 °C for 1 min, with fluorescence acquisition during annealing/extension; genotypes were automatically determined by allelic discrimination using QuantStudio Software v1.3 based on fluorescence intensity.
All reactions were run in duplicate to ensure reproducibility. Negative controls (no template controls, NTCs) were included in each run to detect potential contamination.

2.2. Statistical Analysis

Statistical analyses included descriptive summaries (counts and percentages) and inferential comparisons using Pearson’s chi-square test or Fisher’s exact test, as appropriate. All analyses were performed using IBM SPSS Statistics version 22, with statistical significance set at p < 0.05.

3. Results

The study cohort consisted of 83 patients diagnosed with colorectal adenocarcinoma, all of them with identifiable KRAS rs61764370 polymorphism status.

3.1. Demographic and Clinical Characteristics of the Study Population

The sex distribution showed a slight male predominance, with 47 men (56.6%) and 36 women (43.4%).
The youngest patient was 45 years old, while the oldest was 87 years old at the time of diagnosis—a range consistent with the epidemiological profile of colorectal cancer, which predominantly affects older adults. The mean age at diagnosis was 68.6 years.
Tumor localization was almost equally distributed, with 46 cases (55.4%) originating in the colon and 37 cases (44.6%) in the rectum.
Regarding disease stage at diagnosis, most patients were diagnosed with locally advanced or metastatic disease. The most prevalent stage at diagnosis was Stage III (n = 39, 47.0%), followed by Stage IV (n = 20, 24.1%). Earlier stages were less common: twenty-one patients (25.3%) were diagnosed in Stage II and only three patients (3.6%) in Stage I.
Tumor differentiation was predominantly moderate. Grade 2 tumors were identified in 42 patients (50.6%), while 28 patients (33.7%) had well-differentiated (Grade 1) tumors. Poorly differentiated tumors (Grade 3) were found in 13 cases (15.7%).
Invasion-related features were frequent. Perineural invasion (PNI) was present in 39 patients (47.0%) and absent in 44 (53.0%), while lymphovascular invasion (LVI) was present in 35 patients (42.2%) and absent in 48 (57.8%). Co-occurrence of both PNI and LVI was observed in 22 cases (26.5%).
These data reflect a clinically heterogeneous CRC population, representative of real-world diagnostic distributions and staging, with a predominance of advanced-stage and moderately differentiated tumors.
Genetic analysis revealed that 64 patients (77.1%) were homozygous for the wild-type TT genotype, while 19 patients (22.9%) were heterozygous TG carriers of the rs61764370 SNP. (Figure 1).

3.2. Demographic and Clinical Characteristics of rs61764370 SNP Subgroups

Demographic characteristics were balanced between the rs61764370 SNP subgroups.
In the TT group, thirty-seven of sixty-four patients (57.8%) were male and there were twenty-seven (42.2%) females, compared to ten males (52.6%) and nine females (47.4%) out of nineteen patients in the TG group. No significant difference in sex distribution was observed (p = 0.689).
Similarly, tumor localization was comparable between genotype groups: 36 of 64 TT patients (56.3%) had tumors located in the colon and 28 (43.8%) in the rectum, while among the nineteen heterozygote TG patients, ten (52.6%) had colonic tumors and nine (47.4%) had rectal tumors (p = 0.781).
Regarding stage at diagnosis, early-stage disease (AJCC Stage I–II) was present in eighteen of sixty-four TT patients (28.1%) and six of nineteen TG patients (31.6%), whereas advanced-stage disease (Stage III–IV) was observed in forty-six TT (71.9%) and thirteen TG patients (68.4%), relative to their respective subgroup totals. The distribution of disease stage did not differ significantly between groups (Fisher’s exact test, p = 0.812) (Figure 2).
Histopathologically, a notable finding was that poorly differentiated tumors (Grade 3) were present in 13 of 64 TT patients (20.3%) but absent in the 19 TG group altogether (0%), which is a difference that approached statistical significance (Fisher’s exact test, p = 0.06) (Table 2).
When tumor grade was dichotomized into low-grade (G1) and high-grade (G2 or G3), low-grade tumors (Grade 1) were more frequent among TG patients—accounting for nine of nineteen cases (47.4%), compared with nineteen of sixty-four cases (29.7%) in the TT group. Although this difference did not reach significance (p = 0.152), it supported the observed trend toward more favorable histological differentiation in TG carriers (Figure 3).
Analysis of a composite tumor aggressiveness score, defined by the presence of any of the following: Grade 3 differentiation, perineural invasion (PNI), or lymphovascular invasion (LVI) revealed a lower proportion of high-aggressiveness tumors among TG patients (seven of nineteen; 36.8%) compared to TT patients (thirty-one of sixty-four; 48.4%). Although this difference was not statistically significant (p = 0.422), it aligned with the overall trend, suggesting a less aggressive tumor phenotype in TG carriers (Figure 4).
Finally, co-occurrence of both PNI and LVI was almost identical in the two groups: seventeen of sixty-four TT patients (26.6%) and five of nineteen TG patients (26.3%) (p = 0.983) (Figure 5).
While none of these comparisons achieved statistical significance, the patterns suggest a more favorable histopathological profile in TG carriers.

4. Discussion

Although no statistically significant associations were observed in this pilot analysis, rs61764370 SNP seems to show a trend toward less aggressive tumor behavior in carriers of the variant genotype (TG). In our study population, none of the patients with the TG genotype had poorly differentiated tumors, and more frequently, they were classified as Grade 1. Moreover, in the analysis based on the composite score, the number of patients with “high-aggressiveness” tumors (presence of one or more features: G3, LVI, and/or PNI) was lower in the TG group compared to the TT group. It is important to note that different histological subtypes carry different grades of aggressiveness [32]. Consequently, we purposefully excluded heterogeneous subtypes by selecting a cohort that consisted solely of adenocarcinoma, the most common form.
The central prognostic importance of histopathological parameters such as tumor differentiation, lymphovascular invasion, and perineural invasion is well-established in colorectal cancer and may, in practice, outweigh the impact of individual germline molecular variants. This concept is supported by recent data from a retrospective cohort of colorectal cancer patients treated with reduced-dose 5-fluorouracil, in which tumor differentiation grade and invasion-related features emerged as the strongest independent predictors of overall survival, whereas KRAS mutation status did not demonstrate independent prognostic significance [33].
These findings reinforce the biological and clinical relevance of the histopathological features selected for the composite aggressiveness score in the present study and suggest that subtle germline regulatory variants, such as rs61764370, may exert modulatory rather than dominant prognostic effects.
In terms of underlying mechanisms, the G allele disrupts let-7 miRNA binding within the KRAS 3′UTR, potentially resulting in increased KRAS expression. However, paradoxically, our results suggest a more favorable histopathological profile in G allele carriers, which implies that the downstream effects of this variant may be context-dependent or influenced by other molecular pathways.
The apparent paradox observed in our cohort—where carriers of the G allele showed trends toward more favorable histopathological features despite the predicted increase in KRAS expression—may reflect the complex, context-dependent nature of microRNA-mediated regulation in colorectal cancer. Recent tissue-based analyses of miRNA expression profiles in colon carcinoma have demonstrated that tumor–normal differences in key microRNAs are robust, whereas associations with tumor stage, grade, lymphovascular invasion, or perineural invasion are weak or absent [34]. Notably, tumor-suppressive microRNAs such as miR-185 and miR-141, as well as the oncogenic miR-21, exhibited limited correlation with classical markers of aggressiveness, underscoring that miRNA-driven regulatory effects may influence tumor biology without translating directly into conventional histopathological phenotypes.
Our findings align with those of Smits et al., who reported no statistically significant link between rs61764370 and CRC outcomes, though early-stage disease trends were observed in G allele carriers [29].
Similarly, Kjersem et al. found no predictive impact of the variant in cetuximab-treated patients [28], while Langevin et al.’s meta-analysis concluded that evidence for prognostic relevance remains inconsistent [31].
In contrast, Saridaki et al. noted improved outcomes in G allele carriers treated with anti-EGFR therapy, suggesting potential predictive rather than prognostic roles in specific therapeutic contexts [27].
Beyond colorectal cancer, Ratner et al. demonstrated that the KRAS variant is linked to poorer outcomes and platinum resistance in ovarian cancer, which underscores its broader potential as a biomarker of aggressive behavior in certain tumor types [18].
Importantly, most previous studies focused on treatment response or survival endpoints, whereas our analysis explores correlations with established adverse histological features—a novel perspective that may add value to clinicopathological risk stratification.
Furthermore, considering the recent focus on quality of life [35,36,37] in oncological patients, it is important to mention that a recent prospective study by Schenker et al. (2025) [38] evaluated quality-of-life outcomes in rectal cancer patients undergoing chemoradiotherapy, highlighting significant functional decline—particularly in emotional and gastrointestinal domains, most notably among those who required a stoma. This is clinically relevant, as adverse histopathological features such as high-grade differentiation, perineural invasion, and lymphovascular invasion often inform surgical decisions, including stoma formation. Given that the TG genotype group in our study exhibited fewer of these high-risk pathological features, it is plausible that these patients may have had a lower likelihood of requiring a stoma, which in turn could contribute to improved post-treatment quality of life. These findings suggest a potential link between germline variation, tumor biology, surgical management, and patient-centered outcomes.
The present study has several limitations, most notably the relatively small sample size. In addition, the low frequency of the TG genotype, the single-center design, and the absence of multivariate modeling that includes other potentially confounding or effect-modifying molecular markers (e.g., KRAS mutation status, MSI, and BRAF) should be acknowledged [39].
Nonetheless, the integration of histology and germline variation remains underexplored in CRC.
Despite the extensive investigation of miRNA polymorphisms in colorectal cancer, our study was specifically designed to explore regional variations by comparing cohorts from different ancestral backgrounds. For instance, the rs895819 variant in pre-miR 27a has been associated with increased colorectal cancer susceptibility in Han Chinese populations, with the GG genotype linked to elevated risk and progression [40,41]. Conversely, studies conducted in European cohorts have found no significant association between miR 27a (rs895819), miR 146a, miR 196a 2, miR 492, or miR 608 polymorphisms and colorectal cancer risk [42,43]. Additionally, other research in Chinese populations has reinforced the significant link between rs895819 and colorectal cancer susceptibility [44,45]. These divergent findings between Chinese and European populations underscore the necessity of conducting region-specific analyses. Our cohort, therefore, offers a valuable opportunity to identify population-specific genetic risk factors and deepen our understanding of how regional genetic backgrounds may influence the role of miRNA polymorphisms in colorectal cancer.
Collectively, these observations are consistent with emerging evidence, suggesting that molecular and epigenetic biomarkers in colorectal cancer frequently demonstrate stronger diagnostic or biological relevance than direct prognostic value. Large-scale analyses of miRNA expression profiles have shown clear tumor–normal discrimination but minimal association with survival or invasion-related endpoints [34], while clinical outcome studies continue to identify histological grade and invasion patterns as the primary determinants of prognosis irrespective of KRAS mutational status [33]. Within this framework, rs61764370 may represent a biologically relevant modifier of tumor behavior whose effects are subtle, context-dependent, and insufficient alone to override established histopathological risk factors.
Future research should prioritize multicenter, prospectively collected cohorts with comprehensive multivariate adjustments, incorporating integrated molecular–histopathological risk models to enhance clinical applicability. This approach is reinforced by recent findings from a Romanian cohort showing a significant association between the GAS5 rs145204276 ins/del polymorphism and colorectal cancer risk—particularly among patients with distal colon tumors, advanced stages, and poorly differentiated histology [46]. These results highlight how regional and histopathological factors may modulate genetic associations, thereby underscoring the value of combining molecular data with tumor-specific pathological features in multicenter studies.

5. Conclusions

In this study of patients with histologically confirmed colorectal adenocarcinoma, the rs61764370 TG genotype was not significantly associated with unfavorable histopathological features. Nevertheless, TG carriers showed a tendency toward lower-grade tumors and reduced histopathological aggressiveness compared with wild-type TT carriers. Although these observations do not support a definitive protective effect, they may reflect underlying biological differences, potentially related to altered microRNA binding and modulation of KRAS signaling pathways, which could influence tumor differentiation and progression. These partial findings should be interpreted cautiously given the limited sample size, and they should therefore be interpreted as exploratory observations that may provide preliminary insight pending confirmation in larger, independent cohorts to clarify the biological and clinical relevance of the rs61764370 polymorphism in colorectal cancer.

Author Contributions

Conceptualization, T.C.B., F.B., M.G.C., M.-L.C. and M.S.; methodology, T.C.B., F.B., M.G.C. and M.S.; software, M.-L.C. and T.C.B.; validation, All authors; formal analysis T.C.B., M.G.C. and M.-L.C.; investigation, T.C.B., M.G.C., S.S.S., F.B., M.-L.C. and M.S.; resources, T.C.B., M.G.C., F.B. and M.S.; data curation, T.C.B., P.O.S. and C.S.M.; writing—original draft preparation, T.C.B., F.B., M.G.C., A.C.-D., M.-L.C. and M.S.; writing—review and editing, F.B., M.G.C., M.-L.C. and M.S.; visualization, A.C.-D., S.S.S., A.-M.C., A.M.M., P.O.S., R.A.S. and C.S.M.; supervision M.S., F.B. and M.-L.C.; project administration, M.S. All authors have read and agreed to the published version of the manuscript.

Funding

This research was funded by the EU’s NextGenerationEU instrument through the National Recovery and Resilience Plan of Romania, Pillar III-C9-I, section I5, through establishment and operationalization of Competence Centers PNRR-III-C9-2022-I5, managed by the Ministry of Research, Innovation and Digitalization, within the project entitled “Creation, Operational and Development of the National Center of Competence in the field of Cancer”, contract no. 760009/30.12.2022, code CF 14/16.11.2022. The Article Processing Charges were funded by the University of Medicine and Pharmacy of Craiova, Romania.

Institutional Review Board Statement

This study was conducted in accordance with the Declaration of Helsinki, first established in 1975 and revised in 2013. It received approval from the Ethics Committee of the University of Medicine and Pharmacy of Craiova nr.245/25.10.2023, date of approval 25 October 2023.

Informed Consent Statement

Written informed consent has been obtained from all subjects involved in the study.

Data Availability Statement

The original contributions presented in this study are included in the article material. Further inquiries can be directed at the corresponding authors.

Conflicts of Interest

The authors declare no conflicts of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.

Abbreviations

The following abbreviations are used in this manuscript:
CRCColorectal cancer
GLOBOCANGlobal Cancer Observatory
TNMTumor, Node, Metastasis
LVILymphovascular invasion
PNIPerineural invasion
3′UTR3′ untranslated region
LCS6let-7 microRNA binding site
SNPSingle-Nucleotide Polymorphisms
KRASKirsten rat sarcoma virus
MAPKMitogen-activated protein kinase
RNARibonucleic acid
DNADeoxyribonucleic acid
MSIMicrosatellite Instability
EGFREpidermal growth factor receptor

References

  1. Xi, Y.; Xu, P. Global colorectal cancer burden in 2020 and projections to 2040. Transl. Oncol. 2021, 14, 101174. [Google Scholar] [CrossRef]
  2. Morgan, E.; Arnold, M.; Gini, A.; Lorenzoni, V.; Cabasag, C.J.; Laversanne, M.; Vignat, J.; Ferlay, J.; Murphy, N.; Bray, F. Global burden of colorectal cancer in 2020 and 2040: Incidence and mortality estimates from GLOBOCAN. Gut 2023, 72, 338–344. [Google Scholar] [CrossRef] [PubMed]
  3. Bray, F.; Laversanne, M.; Sung, H.; Ferlay, J.; Siegel, R.L.; Soerjomataram, I.; Jemal, A. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2024, 74, 229–263. [Google Scholar] [CrossRef] [PubMed]
  4. IARC. GLOBOCAN 2022: Colorectal Cancer Factsheet. Available online: https://gco.iarc.who.int (accessed on 16 July 2025).
  5. Fang, S.H.; Efron, J.E.; Berho, M.E.; Wexner, S.D. Dilemma of stage II colon cancer and decision making for adjuvant chemotherapy. J. Am. Coll. Surg. 2014, 219, 1056–1069. [Google Scholar] [CrossRef] [PubMed]
  6. Puppa, G.; Sonzogni, A.; Colombari, R.; Pelosi, G. TNM staging system of colorectal carcinoma: A critical appraisal of challenging issues. Arch. Pathol. Lab. Med. 2010, 134, 837–852. [Google Scholar] [CrossRef]
  7. Chen, K.; Collins, G.; Wang, H.; Toh, J.W.T. Pathological Features and Prognostication in Colorectal Cancer. Curr. Oncol. 2021, 28, 5356–5383. [Google Scholar] [CrossRef]
  8. Al-Sukhni, E.; Attwood, K.; Gabriel, E.M.; LeVea, C.M.; Kanehira, K.; Nurkin, S.J. Lymphovascular and perineural invasion are associated with poor prognostic features and outcomes in colorectal cancer: A retrospective cohort study. Int. J. Surg. 2017, 37, 42–49. [Google Scholar] [CrossRef]
  9. Skancke, M.; Arnott, S.M.; Amdur, R.L.; Siegel, R.S.; Obias, V.J.; Umapathi, B.A. Lymphovascular Invasion and Perineural Invasion Negatively Impact Overall Survival for Stage II Adenocarcinoma of the Colon. Dis. Colon. Rectum 2019, 62, 181–188. [Google Scholar] [CrossRef]
  10. Cienfuegos, J.A.; Martinez, P.; Baixauli, J.; Beorlegui, C.; Rosenstone, S.; Sola, J.J.; Rodriguez, J.; Hernandez-Lizoain, J.L. Perineural Invasion is a Major Prognostic and Predictive Factor of Response to Adjuvant Chemotherapy in Stage I–II Colon Cancer. Ann. Surg. Oncol. 2017, 24, 1077–1084. [Google Scholar] [CrossRef]
  11. Gao, Z.; Cao, H.; Xu, X.; Wang, Q.; Wu, Y.; Lu, Q. Prognostic value of lymphovascular invasion in stage II colorectal cancer patients with an inadequate examination of lymph nodes. World J. Surg. Oncol. 2021, 19, 125. [Google Scholar] [CrossRef]
  12. Rogers, A.C.; Winter, D.C.; Heeney, A.; Gibbons, D.; Lugli, A.; Puppa, G.; Sheahan, K. Systematic review and meta-analysis of the impact of tumour budding in colorectal cancer. Br. J. Cancer 2016, 115, 831–840. [Google Scholar] [CrossRef] [PubMed]
  13. Sebio, A.; Pare, L.; Paez, D.; Salazar, J.; Gonzalez, A.; Sala, N.; del Rio, E.; Martin-Richard, M.; Tobena, M.; Barnadas, A.; et al. The LCS6 polymorphism in the binding site of let-7 microRNA to the KRAS 3′-untranslated region: Its role in the efficacy of anti-EGFR-based therapy in metastatic colorectal cancer patients. Pharmacogenet. Genom. 2013, 23, 142–147. [Google Scholar] [CrossRef] [PubMed]
  14. Crowley, E.H.; Arena, S.; Lamba, S.; Di Nicolantonio, F.; Bardelli, A. Targeted knock-in of the polymorphism rs61764370 does not affect KRAS expression but reduces let-7 levels. Hum. Mutat. 2014, 35, 208–214. [Google Scholar] [CrossRef] [PubMed]
  15. Uvirova, M.; Simova, J.; Kubova, B.; Dvorackova, N.; Tomaskova, H.; Sedivcova, M.; Dite, P. Comparison of the prevalence of KRAS-LCS6 polymorphism (rs61764370) within different tumour types (colorectal, breast, non-small cell lung cancer and brain tumours). A study of the Czech population. Biomed. Pap. Med. Fac. Univ. Palacky Olomouc Czech Repub. 2015, 159, 466–471. [Google Scholar] [CrossRef]
  16. Ying, H.Q.; Wang, F.; He, B.S.; Pan, Y.Q.; Gao, T.Y.; Xu, Y.Q.; Li, R.; Deng, Q.W.; Sun, H.L.; Wang, S.K. The involvement of Kras gene 3′-UTR polymorphisms in risk of cancer and influence on patient response to anti-EGFR therapy in metastatic colorectal cancer: A meta-analysis. OncoTargets Ther. 2014, 7, 1487–1496. [Google Scholar] [CrossRef]
  17. Sclafani, F.; Chau, I.; Cunningham, D.; Peckitt, C.; Lampis, A.; Hahne, J.C.; Braconi, C.; Tabernero, J.; Glimelius, B.; Cervantes, A.; et al. Prognostic role of the LCS6 KRAS variant in locally advanced rectal cancer: Results of the EXPERT-C trial. Ann. Oncol. 2015, 26, 1936–1941. [Google Scholar] [CrossRef]
  18. Ratner, E.S.; Keane, F.K.; Lindner, R.; Tassi, R.A.; Paranjape, T.; Glasgow, M.; Nallur, S.; Deng, Y.; Lu, L.; Steele, L.; et al. A KRAS variant is a biomarker of poor outcome, platinum chemotherapy resistance and a potential target for therapy in ovarian cancer. Oncogene 2012, 31, 4559–4566. [Google Scholar] [CrossRef]
  19. Reinhart, B.J.; Slack, F.J.; Basson, M.; Pasquinelli, A.E.; Bettinger, J.C.; Rougvie, A.E.; Horvitz, H.R.; Ruvkun, G. The 21-nucleotide let-7 RNA regulates developmental timing in Caenorhabditis elegans. Nature 2000, 403, 901–906. [Google Scholar] [CrossRef]
  20. Pasquinelli, A.E.; Reinhart, B.J.; Slack, F.; Martindale, M.Q.; Kuroda, M.I.; Maller, B.; Hayward, D.C.; Ball, E.E.; Degnan, B.; Muller, P.; et al. Conservation of the sequence and temporal expression of let-7 heterochronic regulatory RNA. Nature 2000, 408, 86–89. [Google Scholar] [CrossRef]
  21. Johnson, S.M.; Grosshans, H.; Shingara, J.; Byrom, M.; Jarvis, R.; Cheng, A.; Labourier, E.; Reinert, K.L.; Brown, D.; Slack, F.J. RAS is regulated by the let-7 microRNA family. Cell 2005, 120, 635–647. [Google Scholar] [CrossRef]
  22. Esquela-Kerscher, A.; Slack, F.J. Oncomirs—microRNAs with a role in cancer. Nat. Rev. Cancer 2006, 6, 259–269. [Google Scholar] [CrossRef]
  23. Chin, L.J.; Ratner, E.; Leng, S.; Zhai, R.; Nallur, S.; Babar, I.; Muller, R.U.; Straka, E.; Su, L.; Burki, E.A.; et al. A SNP in a let-7 microRNA complementary site in the KRAS 3′ untranslated region increases non-small cell lung cancer risk. Cancer Res. 2008, 68, 8535–8540. [Google Scholar] [CrossRef] [PubMed]
  24. Megiorni, F.; Cialfi, S.; Dominici, C.; Quattrucci, S.; Pizzuti, A. Synergistic post-transcriptional regulation of the Cystic Fibrosis Transmembrane conductance Regulator (CFTR) by miR-101 and miR-494 specific binding. PLoS ONE 2011, 6, e26601. [Google Scholar] [CrossRef] [PubMed]
  25. Saliani, M.; Mirzaiebadizi, A.; Javadmanesh, A.; Siavoshi, A.; Ahmadian, M.R. KRAS-related long noncoding RNAs in human cancers. Cancer Gene Ther. 2022, 29, 418–427. [Google Scholar] [CrossRef] [PubMed]
  26. Chhichholiya, Y.; Singh, H.V.; Vashistha, R.; Singh, S.; Munshi, A. Deciphering the role of KRAS gene in oncogenesis: Focus on signaling pathways, genetic alterations in 3′UTR, KRAS specific miRNAs and therapeutic interventions. Crit. Rev. Oncol. Hematol. 2024, 194, 104250. [Google Scholar] [CrossRef]
  27. Saridaki, Z.; Weidhaas, J.B.; Lenz, H.J.; Laurent-Puig, P.; Jacobs, B.; De Schutter, J.; De Roock, W.; Salzman, D.W.; Zhang, W.; Yang, D.; et al. A let-7 microRNA-binding site polymorphism in KRAS predicts improved outcome in patients with metastatic colorectal cancer treated with salvage cetuximab/panitumumab monotherapy. Clin. Cancer Res. 2014, 20, 4499–4510. [Google Scholar] [CrossRef]
  28. Kjersem, J.B.; Ikdahl, T.; Guren, T.; Skovlund, E.; Sorbye, H.; Hamfjord, J.; Pfeiffer, P.; Glimelius, B.; Kersten, C.; Solvang, H.; et al. Let-7 miRNA-binding site polymorphism in the KRAS 3′UTR; colorectal cancer screening population prevalence and influence on clinical outcome in patients with metastatic colorectal cancer treated with 5-fluorouracil and oxaliplatin +/- cetuximab. BMC Cancer 2012, 12, 534. [Google Scholar] [CrossRef]
  29. Smits, K.M.; Paranjape, T.; Nallur, S.; Wouters, K.A.; Weijenberg, M.P.; Schouten, L.J.; van den Brandt, P.A.; Bosman, F.T.; Weidhaas, J.B.; van Engeland, M. A let-7 microRNA SNP in the KRAS 3′UTR is prognostic in early-stage colorectal cancer. Clin. Cancer Res. 2011, 17, 7723–7731. [Google Scholar] [CrossRef]
  30. Huang, J.; Zang, Q.; Wen, Y.; Pan, Z.; Yao, Z.; Huang, M.; Huang, J.; Chen, J.; Wang, R. Prognostic value of KRAS mutation in patients undergoing pulmonary metastasectomy for colorectal cancer: A systematic review and meta-analysis. Crit. Rev. Oncol. Hematol. 2021, 160, 103308. [Google Scholar] [CrossRef]
  31. Langevin, S.M.; Christensen, B.C. Let-7 microRNA-binding-site polymorphism in the 3′UTR of KRAS and colorectal cancer outcome: A systematic review and meta-analysis. Cancer Med. 2014, 3, 1385–1395. [Google Scholar] [CrossRef]
  32. Phipps, A.I.; Alwers, E.; Harrison, T.; Banbury, B.; Brenner, H.; Campbell, P.T.; Chang-Claude, J.; Buchanan, D.; Chan, A.T.; Farris, A.B.; et al. Association Between Molecular Subtypes of Colorectal Tumors and Patient Survival, Based on Pooled Analysis of 7 International Studies. Gastroenterology 2020, 158, 2158–2168.e4. [Google Scholar] [CrossRef]
  33. Chen, M.W.; Ou, J.J.; Chang, C.S. Prognostic Factors and Biomarker Performance in Patients with Colorectal Cancer Receiving Reduced-Dose 5-Fluorouracil Therapy: A Retrospective Cohort Analysis. J. Clin. Med. 2025, 15, 71. [Google Scholar] [CrossRef]
  34. Krsul, D.; Prenc, E.; Pozgaj, L.; Stefok, D.; Pongrac, P.; Podolski, M.; Radicevic, A.P.; Karlovic, D.; Jerkovic, A.; Golcic, M.; et al. Diagnostic Relevance of miR-185, miR-141, and miR-21 in Colon Carcinoma: Insights into Tumor Sidedness and Reference Gene Selection. Biomedicines 2025, 13, 2460. [Google Scholar] [CrossRef] [PubMed]
  35. Dunn, J.; Lynch, B.; Aitken, J.; Leggett, B.; Pakenham, K.; Newman, B. Quality of life and colorectal cancer: A review. Aust. N. Z. J. Public Health 2003, 27, 41–53. [Google Scholar] [CrossRef] [PubMed]
  36. O’Gorman, C.; Denieffe, S.; Gooney, M. Literature review: Preoperative radiotherapy and rectal cancer—Impact on acute symptom presentation and quality of life. J. Clin. Nurs. 2014, 23, 333–351. [Google Scholar] [CrossRef] [PubMed]
  37. Guren, M.G.; Dueland, S.; Skovlund, E.; Fossa, S.D.; Poulsen, J.P.; Tveit, K.M. Quality of life during radiotherapy for rectal cancer. Eur. J. Cancer 2003, 39, 587–594. [Google Scholar] [CrossRef]
  38. Schenker, M.; Bitina, L.C.; Schenker, R.A.; Ciurea, A.M.; Mehedinteanu, A.M.; Berisha, T.C.; Bratu, L.D.; Cara, M.L.; Dicianu, A.M.; Stovicek, P.O. Prospective Evaluation of the Influence of Chemoradiotherapy and Stoma on Functional and Symptomatic Outcomes in Rectal Cancer Patients. Cancers 2025, 17, 2052. [Google Scholar] [CrossRef]
  39. Schneider, N.I.; Langner, C. Prognostic stratification of colorectal cancer patients: Current perspectives. Cancer Manag. Res. 2014, 6, 291–300. [Google Scholar] [CrossRef]
  40. Jiang, Y.; Lin, D.H.; Xu, J.P.; Chen, W.X.; Zheng, S.J.; Song, L. Genotype GG of rs895819 Functional Polymorphism Within miR-27a Might Increase Genetic Susceptibility to Colorectal Cancer in Han Chinese Population. J. Clin. Lab. Anal. 2016, 30, 351–355. [Google Scholar] [CrossRef]
  41. Wang, Z.; Sun, X.; Wang, Y.; Liu, X.; Xuan, Y.; Hu, S. Association between miR-27a genetic variants and susceptibility to colorectal cancer. Diagn. Pathol. 2014, 9, 146. [Google Scholar] [CrossRef]
  42. Kupcinskas, J.; Bruzaite, I.; Juzenas, S.; Gyvyte, U.; Jonaitis, L.; Kiudelis, G.; Skieceviciene, J.; Leja, M.; Pauzas, H.; Tamelis, A.; et al. Lack of association between miR-27a, miR-146a, miR-196a-2, miR-492 and miR-608 gene polymorphisms and colorectal cancer. Sci. Rep. 2014, 4, 5993. [Google Scholar] [CrossRef]
  43. Hezova, R.; Kovarikova, A.; Bienertova-Vasku, J.; Sachlova, M.; Redova, M.; Vasku, A.; Svoboda, M.; Radova, L.; Kiss, I.; Vyzula, R.; et al. Evaluation of SNPs in miR-196-a2, miR-27a and miR-146a as risk factors of colorectal cancer. World J. Gastroenterol. 2012, 18, 2827–2831. [Google Scholar] [CrossRef]
  44. Zhang, S.; Han, Q.; Zhu, K.; Wang, Q. The association of miR-27a rs895819 polymorphism with colorectal cancer risk in Chinese population. J. Clin. Lab. Anal. 2020, 34, e23497. [Google Scholar] [CrossRef]
  45. Bian, Q.; Chen, J.J.; Gu, J.P.; Xu, J. Association between pre-miR-27a functional polymorphism and risk of colorectal cancer in north Chinese Han population. OncoTargets Ther. 2015, 8, 3003–3007. [Google Scholar] [CrossRef]
  46. Mirea, C.S.; Schenker, M.; Petre-Mandache, B.; Cucu, M.G.; Camen, G.C.; Vilcea, I.D.; Albu, B.C.; Obleaga, C.V.; Ciorbagiu, M.C.; Streata, I.; et al. GAS5 rs145204276 Ins/Del Polymorphism Is Associated with CRC Susceptibility in a Romanian Population. Int. J. Mol. Sci. 2025, 26, 3078. [Google Scholar] [CrossRef]
Biomedicines 14 00319 g001
Figure 1. Distribution of TT and TG genotypes in the CRC patient population.
Figure 1. Distribution of TT and TG genotypes in the CRC patient population.
Biomedicines 14 00319 g001
Biomedicines 14 00319 g002
Figure 2. Distribution of tumor stage at diagnosis according to TT (wild-type) and TG (heterozygous) genotypes.
Figure 2. Distribution of tumor stage at diagnosis according to TT (wild-type) and TG (heterozygous) genotypes.
Biomedicines 14 00319 g002
Biomedicines 14 00319 g003
Figure 3. Distribution of tumor grade according to TT (wild-type) and TG (heterozygous) genotypes.
Figure 3. Distribution of tumor grade according to TT (wild-type) and TG (heterozygous) genotypes.
Biomedicines 14 00319 g003
Biomedicines 14 00319 g004
Figure 4. Distribution of tumor aggressiveness to TT (wild-type) and TG (heterozygous) genotypes.
Figure 4. Distribution of tumor aggressiveness to TT (wild-type) and TG (heterozygous) genotypes.
Biomedicines 14 00319 g004
Biomedicines 14 00319 g005
Figure 5. Distribution of co-occurrence of both PNI and LVI status to TT (wild-type) and TG (heterozygous) genotypes.
Figure 5. Distribution of co-occurrence of both PNI and LVI status to TT (wild-type) and TG (heterozygous) genotypes.
Biomedicines 14 00319 g005
Table 1. Baseline characteristics of patients included in study.
Table 1. Baseline characteristics of patients included in study.
VariableColorectal Cancer
Number of cases83
Median age at diagnostic68 (Min = 45–Max = 87)
Gender
  • F
36 (43.4%)
  • M
47 (56.6%)
Location
  • colon
46 (55.4%)
  • rect
37 (44.6%)
Tumor stage at diagnostic
  • I
3 (3.6%)
  • II
21 (25.3%)
  • III
39 (47%)
  • IIV
20 (24.1%)
Differentiation Grade
  • Grade 1
28 (33.7%)
  • Grade 2
42 (50.6%)
  • Grade 3
13 (15.75)
Perineural invasion
  • present
39 (47%)
  • absent
44 (53%)
Lymphovascular invasion
  • present
35 (42.2%)
  • absent
48 (57.8%)
Table 2. Tumor grade distribution according to rs61764370 genotype.
Table 2. Tumor grade distribution according to rs61764370 genotype.
Tumor GradeHomozygous TTHeterozygous TGp-Value
119 (29.7%)9 (47.4%)0.06
232 (50.0%)10 (52.6%)
313 (20.3%)0 (0.0%)
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Berisha, T.C.; Cucu, M.G.; Calotă-Dobrescu, A.; Sosoi, S.S.; Ciurea, A.-M.; Mehedințeanu, A.M.; Stovicek, P.O.; Schenker, R.A.; Mirea, C.S.; Cara, M.-L.; et al. Adverse Histopathological Features in Colorectal Cancer Associated with KRAS rs61764370 SNP: A Preliminary Study. Biomedicines 2026, 14, 319. https://doi.org/10.3390/biomedicines14020319

AMA Style

Berisha TC, Cucu MG, Calotă-Dobrescu A, Sosoi SS, Ciurea A-M, Mehedințeanu AM, Stovicek PO, Schenker RA, Mirea CS, Cara M-L, et al. Adverse Histopathological Features in Colorectal Cancer Associated with KRAS rs61764370 SNP: A Preliminary Study. Biomedicines. 2026; 14(2):319. https://doi.org/10.3390/biomedicines14020319

Chicago/Turabian Style

Berisha, Tradian Ciprian, Mihai Gabriel Cucu, Alexandru Calotă-Dobrescu, Simona Serban Sosoi, Ana-Maria Ciurea, Alina Maria Mehedințeanu, Puiu Olivian Stovicek, Ramona Adriana Schenker, Cecil Sorin Mirea, Monica-Laura Cara, and et al. 2026. "Adverse Histopathological Features in Colorectal Cancer Associated with KRAS rs61764370 SNP: A Preliminary Study" Biomedicines 14, no. 2: 319. https://doi.org/10.3390/biomedicines14020319

APA Style

Berisha, T. C., Cucu, M. G., Calotă-Dobrescu, A., Sosoi, S. S., Ciurea, A.-M., Mehedințeanu, A. M., Stovicek, P. O., Schenker, R. A., Mirea, C. S., Cara, M.-L., Burada, F., & Schenker, M. (2026). Adverse Histopathological Features in Colorectal Cancer Associated with KRAS rs61764370 SNP: A Preliminary Study. Biomedicines, 14(2), 319. https://doi.org/10.3390/biomedicines14020319

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop